Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01021280
Other study ID # Sor492809ctil
Secondary ID
Status Not yet recruiting
Phase N/A
First received November 25, 2009
Last updated June 13, 2012
Start date January 2013
Est. completion date June 2014

Study information

Verified date June 2012
Source Soroka University Medical Center
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

Parathyroid hormone (PTH) gland calcium sensing receptor (CASR) regulates PTH secretion. CASR is also expressed in nephron thick ascending limb (TAL). Bartter syndrome (BS), a normotensive hypokalemic tubulopathy, may be due to mutations in different TAL channels, including the potassium channel ROMK. Mutations in CASR may also cause BS through its effects on ROMK function. However, it is unknown whether ROMK mutations exert any effects on CASR function and PTH physiology. Preliminary data from our center shows that PTH levels were specifically elevated in type II (where ROMK is mutated) and not in type IV (where another gene, Barttin is defective) BS, without a common explanation. We assume that the mutation in ROMK may cause a dysregulation of PTH secretion via possible interaction with CASR.

The purpose of this study is: to investigate the PT-gland function and regulation in BS.

Methods: Patients with BS type II and IV and normal controls will undergo a standard protocol of controlled ionic hypo- and hypercalcemia, during which PTH secretion, phosphate balance and calcium excretion will be followed. Calcium Vs PTH response curves will be generated and compared.

Expected impact and benefit: the results of this study will help understand the mechanisms of PTH regulation beyond CASR.


Description:

The parathyroid glands play a pivotal physiological function by maintaining blood calcium levels, specifically blood ionized calcium concentrations, within a very narrow range. They do so by modulating the minute-to-minute release of parathyroid hormone (PTH) into the circulation. Such changes have almost immediate effects on calcium excretion in the urine and on calcium efflux from bone and, if sustained for hours or days, affect renal vitamin D metabolism and ultimately the efficiency of intestinal calcium absorption. The capacity of chief cells of the parathyroid to detect small changes in blood ionized calcium levels, modify PTH release accordingly, and initiate these adaptive responses is mediated by a calcium-sensing receptor (CaSR) located at the cell surface.

The importance of the CaSR in parathyroid tissue extends beyond its traditional role as a modifier of calcium-regulated PTH secretion to involve other key components of parathyroid gland function that are frequently abnormal in clinical disorders characterized by excess parathyroid gland activity such as hyperparathyroidism. These include disturbances in the control of PTH gene transcription and hormone synthesis and the development of parathyroid gland enlargement due to tissue hyperplasia.

PTH acts mainly on renal proximal tubule phosphorus (Pi) reabsorption and bone osteoclast calcium and Pi resorption. CASR is also expressed in nephron thick ascending limb (TAL), where it interacts with luminal potassium ROMK channel. Mutations in several TAL channels and proteins (including ROMK, NKCC2, ClCKb, Barttin and CASR) cause Bartter syndrome (BS), a normotensive hypokalemic tubulopathy. Whereas the effects of CASR mutations on ROMK function in the kidney have been described , it is unknown whether ROMK mutations exert any effects on CASR function or PTH regulation. We describe here a group of children and adolescents with type II BS (due to mutations in ROMK) with abnormal PTH homeostasis.

Preliminary Data:

We compared laboratory data of 12 children with type II BS (4M, 8F) and 17 children (7M, 10F) with type IV BS (d/t mutations in the Barttin gene, a beta subunit of the ClCKb basolateral chloride channel in the TAL ), followed in our center over the past 10 years. A total of 86 and 105 datasets of blood and urine analyses (average datasets/pt: 7.3±4.1 and 6.9±2.9), for type II and IV BS respectively, were analyzed.Potassium levels were normal in all BS-II children without additional salt supplementation, whereas BS-IV children were usually mildly hypokalemic. Estimated GFR remains normal in all children. There was no hypomagnesemia. Average PTH values were significantly higher in BS-II (102±39 Vs 46±24 pg/ml in BS-IV, p<0.001) and were above upper normal limit in 93% of cases Vs 13% in BS-IV (p<0.001). Levels of 25(OH) vitamin D were not different. Total serum calcium was mildly decreased (within the normal range) and serum Pi increased in BS-II, both in absolute values or when normalized for age (PiSDS). The threshold for phosphate excretion (TpGFR) was slightly higher in BS-II. There was no difference in the degree of hypercalciuria between groups. Based on these preliminary data we concluded that the elevated PTH levels only in type II BS are not related to a decrease in GFR or vitamin D levels or decreased serum calcium or hypercalciuria. The elevated Pi levels are associated with a decrease in phosphate excretion, but are not correlated with PTH levels. The possibility that a mutation in ROMK may cause a dysregulation of PTH secretion via possible interaction with CASR should now be investigated.

Methods:

The investigative protocol has been submitted to the local Committee for Human Experimentation. Informed consent will be obtained from affected children (or young adults) and their parents.

We expect to recruit 5 patients from each BS subgroup. In addition we will recruit 5 normal volunteers to serve as an additional control group.

Subjects will be evaluated during 2-day admissions to the General Pediatric Ward as previously described . On the first day of study, 2-h I.V. infusions of sodium citrate will be done to gradually lower blood ionized calcium concentrations to a level of at least 0.2 mmol/L below preinfusion values; the dose of sodium citrate ranges usually from 28-118 mg/kg/h. Blood samples for measurements of ionized calcium and PTH will be obtained 30, 15, and 0 min before and every 10 min during sodium citrate infusions. The following day, 2-h IV infusions of 10% calcium gluconate will be done to gradually raise blood ionized calcium concentrations to a level at least 0.2 mmol/L above preinfusion values. The dose of calcium gluconate usually ranges from 2-8 mg/kg/h. Blood samples for measurements of ionized calcium and PTH will be obtained as described previously for infusions of sodium citrate. The average of measurements obtained 30, 15, and 0 min before starting each infusion will be used to determine basal values for blood ionized calcium and serum PTH for each day of study.

Blood ionized calcium levels will be monitored during calcium infusions using a calcium-specific electrode (Radiometer ICA-II, Copenhagen, Denmark); blood samples will be collected anaerobically, and measurements will be obtained immediately thereafter. Serum samples for PTH determinations will be separated by centrifugation immediately after collection, snap frozen on solid CO2, and stored at -70 oC until assay. Ionized calcium levels will be monitored after stopping calcium infusions until values returned to baseline levels.

The sigmoidal curve that describes the relationship between blood ionized calcium and serum PTH levels will be determined for each study subject using the combined results obtained during sodium citrate and calcium gluconate infusions. According to the four parameter model, the set point for calcium-regulated PTH release represents the ionized calcium concentration at which serum PTH levels are midway between the maximum value achieved during hypocalcemia and the minimum value attained during hypercalcemia, as reported previously .

Results obtained during calcium gluconate infusions will be separately analyzed to assess the inhibitory effect of increasing blood ionized calcium concentrations on PTH release. To improve the linear fit of the data, serum PTH levels, expressed as the natural logarithm (ln) of percent preinfusion values, will be plotted against the corresponding blood ionized calcium concentration at each 10-min interval as previously described .

Statistical Analysis:

Linear regression analysis will be done using the method of least squares, and slope and y-intercept values will be compared using the t statistic. A mono-exponential curve fitting algorithm of the form y =A e-2kt + B will be also used to examine the curvilinear relationship between blood ionized calcium and serum PTH levels during I.V. calcium infusions; these results will be presented as mean values with 95% confidence intervals.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date June 2014
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 14 Years to 35 Years
Eligibility Inclusion Criteria:

- Bartter syndrome

- Normal Vitamin D status

Exclusion Criteria:

- Age < 14 yrs

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Soroka University medical Center Beer Sheva

Sponsors (2)

Lead Sponsor Collaborator
Soroka University Medical Center Ben-Gurion University of the Negev

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Completed NCT02892253 - Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia N/A
Completed NCT05043584 - Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions N/A
Recruiting NCT05885256 - Clinical Assessment of Low Calcium In traUMa (CALCIUM)
Recruiting NCT04160637 - Is There Benefit From Early Postoperative PTH Monitoring?
Completed NCT00506103 - The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT04012476 - Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy Phase 4
Recruiting NCT05586529 - Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia N/A
Completed NCT01868750 - Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia Phase 2
Terminated NCT00623974 - Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia Phase 2
Completed NCT00668200 - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Phase 4
Completed NCT00630214 - Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Phase 2
Not yet recruiting NCT03685877 - Hypocalcemia in Infants and Children
Terminated NCT00001151 - Studies With 1,25-Dihydroxycholecalciferol Phase 2
Completed NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Phase 3
Not yet recruiting NCT03063060 - The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy N/A
Not yet recruiting NCT04304573 - Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
Recruiting NCT05216419 - Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy Phase 4
Recruiting NCT04775381 - Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation Phase 3
Active, not recruiting NCT01632514 - Vitamin D Deficiency and Postoperative Hypocalcemia Phase 4